Leggatt Group - Skin cancer immunotherapy
About
The main focus of our research is to develop immunotherapies for non-melanoma skin cancers. Our aim is to effectively activate CD8 T cells within the skin to kill tumour cells. To achieve this, we are investigating novel ways to deliver T-cell activating antibodies into the skin tumour microenvironment. The goal is to generate both local anti-tumour immunity and long term, memory CD8 T cells capable of protecting against recurrent tumour or new skin tumours at distant sites.